Featured Products
Our Promise to You
Guaranteed product quality, expert customer support
ONLINE INQUIRY
HNT-34
Cat.No.: CSC-C0601
Source: acute myeloid leukemia
Morphology: round cells growing singly and in clusters in suspension
Culture Properties: suspension
- Specification
- Background
- Scientific Data
- Q & A
- Customer Review
Immunology: CD3 -, CD4 +, CD13 +, CD15 +, CD19 -, CD33 +, CD34 +, HLA-DR +
Viruses: PCR: EBV -, HBV -, HCV -, HIV -, HTLV-I/II -, SMRV -
HNT-34 was established from the peripheral blood of a 45-year-old female patient with acute myeloid leukemia (AML) transformed from chronic myelomonocytic leukemia (CMMoL) with 3q21q26 syndrome. Morphologically, HNT-34 cells are undifferentiated blasts which were negative for myeloperoxidase. HNT-34 cells are positive for CD4, CD13, CD33 and CD34, but negative for CD41a and CD42b. The cells actively proliferated in suspension with a doubling time of 26-27h in the absence of any growth factors. Neither proliferative advantage nor differentiation was observed with the addition of G-CSE GM-CSF, IL-3, TPO, DMSO or PMA.
The establishment of HNT-34 provides a valuable model for studying the biology of myeloid leukemia, exploring the mechanisms of leukemogenesis, and evaluating treatment strategies. At present, the research and application of HNT-34 are mainly focused on studying the efficacy of new anticancer drugs, understanding the mechanisms of drug resistance, and revealing the role of gene mutations in treatment response. HNT-34 has also been used to investigate the impact of the tumor microenvironment on leukemia progression, making it an important tool to advance our understanding of myeloid leukemia and improve clinical outcomes for patients.
NRIP1 Knockdown Affects Proliferation, Viability, and Response to Retinoic Acid in Chromosome 3 Rearranged Acute Myeloid Leukemia Cells
Aberrant expression of Ecotropic Viral Integration Site 1 (EVI1) is a hallmark of acute myeloid leukemia (AML) with inv(3) or t(3;3), which is a disease subtype with especially poor outcome. In studying transcriptomes from AML patients with chromosome 3q rearrangements, we identified a significant upregulation of the Nuclear Receptor Interacting Protein 1 (NRIP1) as well as its adjacent non-coding RNA LOC101927745. NRIP1 knockdown negatively affects the proliferation and survival of 3q-rearranged AML cells and increases their sensitivity to all-trans retinoic acid, suggesting that NRIP1 is relevant for the pathogenesis of inv(3)/t(3;3) AML and could serve as a novel therapeutic target in myeloid malignancies with 3q abnormalities.
Fig. 1. Knockdown of NRIP1 induces apoptosis and increases sensitivity to all-trans retinoic acid in t(3;3) acute myeloid leukemia cells (Grasedieck, Sarah, et al. 2021).
Differential Nucleolar Stress Response in NPM1-Mutated Versus NPM1 wild-type AML cells
Acute myeloid leukemia (AML) with mutated NPM1 accounts for one-third of newly diagnosed AML. Despite recent advances, treatment of relapsed/refractory NPM1-mutated AML remains challenging, with the majority of patients eventually dying due to disease progression. Dactinomycin is a low-cost chemotherapeutic agent, which has been anecdotally reported to induce remission in NPM1-mutated patients, although its mechanism of action remains unclear. To explore whether NPM1-mutated cells may have lower thresholds for nucleolar stress response than NPM1 wild-type cells, we exposed to dactinomycin OCI-AML3 and IMS-M2 cells as well as OCI-AML2 and HNT-34 cells, all of which have detectable TP53 levels by western blot. We found that low-dose dactinomycin generates more efficient stress response in cells expressing NPM1 mutant compared to wild-type cells, suggesting that NPM1-mutated AML may be more sensitive to nucleolar stress.
Fig. 2. NPM1mut facilitates nucleolar stress response to dactinomycin (Gionfriddo, Ilaria, et al. 2021).
Cancer karyotypes can be distinguished by the level of their complexity, varying from the presence of only one abnormal chromosome in the diploid set of chromosomes up to very complex karyotypes with almost every chromosome structurally rearranged and/or present in abnormal quantity.
Ask a Question
Average Rating: 5.0 | 1 Scientist has reviewed this product
Consistent results
We have received consistent results with this tumor cell product, giving us confidence in our research findings.
10 Mar 2023
Ease of use
After sales services
Value for money
Write your own review
- You May Also Need
Description: Species: human female; Tissue: lymphocyte, B; Pathology: paroxysmal nocturnal hemoglobinuria; Transformed by: Epstein-Barr
Description: Species: human female; Tissue: lymphocyte, B; Pathology: paroxysmal nocturnal hemoglobinuria; Transformed by: Epstein-Barr
Description: Species: human female; Tissue: lymphocyte, B; Pathology: paroxysmal nocturnal hemoglobinuria; Transformed by: Epstein-Barr
Description: Species: human male 66 years old;
Tissue: lymph node, metastasis;
Tumor: melanoma
Description: Species: human, Black male 11 year old;
Tumor: lymphoma, Burkitt;
Derived from: Raji cell line
